Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial by Blay, Jean-Yves, Prof, Shen, Lin, Prof, Kang, Yoon-Koo, Prof, Rutkowski, Piotr, Prof, Qin, Shukui, Prof, Nosov, Dmitry, MD, Wan, Desen, Prof, Trent, Jonathan, Prof, Srimuninnimit, Vichien, MD, Pápai, Zsuzsanna, MD, Le Cesne, Axel, MD, Novick, Steven, MD, Taningco, Lilia, BS, Mo, Shuyuan, PhD, Green, Steven, MSc, Reichardt, Peter, MD, Demetri, George D, Prof

Get full text